SCHEMBL1118601

SCHEMBL1118601

O=C(Cl)N(c1ccccc1)c1cccc(F)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGIR P43119 4/20 0.49
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39
ALOX15 P16050 1/20 0.39
BCHE P06276 1/20 0.39
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
KAT6A Q92794 1/20 0.36
KDM4E B2RXH2 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1118587 0.88 NPSR1 (0.52) PTGIRNPSR1ALDH1A1NPC1POLB
SCHEMBL1118734 0.87 PTGIR (0.48) PTGIRNPSR1ALDH1A1NPC1POLB
SCHEMBL2093031 0.86 PTGIR (0.51) PTGIRNPSR1ALDH1A1NPC1POLB
SCHEMBL2093029 0.85 PTGIR (0.50) PTGIRNPSR1ALDH1A1NPC1POLB
SCHEMBL1118831 0.80 PTGIR (0.51) PTGIRNPSR1ALDH1A1NPC1POLB
SCHEMBL4617816 0.79 POLB (0.50) PTGIRALDH1A1POLBKMT2ACES2
SCHEMBL5058365 0.77 PTGIR (0.50) PTGIRNPSR1RAB9AKMT2ATDP1
SCHEMBL2090910 0.77 PTGIR (0.59) PTGIRNPSR1ALDH1A1NPC1POLB
SCHEMBL2090908 0.77 PTGIR (0.50) PTGIRNPSR1TDP1ATML3MBTL1
SCHEMBL310005 0.75 NPSR1 (0.64) NPSR1ALDH1A1NPC1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50267-E1 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2025-01-14 US disclosed
US-20250009693-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2025-01-09 US disclosed
US-20230404954-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2023-12-21 US disclosed
EP-3884934-B1 PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID ARENA PHARM INC (US) 2023-12-13 EP disclosed
US-20230121825-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2023-04-20 US disclosed
EP-3884934-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2021-09-29 EP disclosed
EP-2857015-B1 Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto ARENA PHARM INC (US) 2021-05-05 EP disclosed
US-20200375930-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2020-12-03 US disclosed
US-10668033-B2 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2020-06-02 US disclosed
US-20170360730-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2017-12-21 US disclosed
EP-2280696-B9 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2016-01-13 EP disclosed
US-20150126527-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2015-05-07 US disclosed
EP-2857015-A1 Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto Arena Pharmaceuticals, Inc. (US) 2015-04-08 EP disclosed
US-8895776-B2 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2014-11-25 US disclosed
EP-2280696-B1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2014-09-17 EP disclosed
US-20130217706-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-08-22 US disclosed
US-20110053958-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 US disclosed
EP-2280696-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2011-02-09 EP disclosed
WO-2009117095-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053958-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R PTGIR 1/4885NPSR1 2142/4885ALDH1A1 2570/4885
US-20130217706-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, PTGER2 PTGIR 1/4885NPSR1 761/4885ALDH1A1 3056/4885
US-20170360730-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R PTGIR 1/4885NPSR1 2153/4885ALDH1A1 2567/4885
US-20230121825-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, PLOD3 PTGIR 1/4885NPSR1 2093/4885ALDH1A1 2366/4885
US-20200375930-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R PTGIR 1/4885NPSR1 2153/4885ALDH1A1 2567/4885
US-20150126527-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R PTGIR 1/4885NPSR1 2153/4885ALDH1A1 2567/4885
US-10668033-B2 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto PTGIR, PTGIS, TBXA2R PTGIR 1/4885NPSR1 2153/4885ALDH1A1 2567/4885
US-20250009693-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R PTGIR 1/4885NPSR1 2149/4885ALDH1A1 2589/4885
US-20230404954-A1 MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO PTGIR, PTGIS, TBXA2R PTGIR 1/4885NPSR1 2142/4885ALDH1A1 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.